Shanghai Kaibao Pharmaceutical Co., Ltd. (300039) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shanghai Kaibao Pharmaceutical Co., Ltd.

Why is Shanghai Kaibao Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 3.14% and Operating profit at 14.54% over the last 5 years

Negative results in Sep 25

INTEREST(9M) At CNY 0.08 MM has Grown at inf%
NET SALES(Q) At CNY 214.37 MM has Fallen at -26.61%
INTEREST COVERAGE RATIO(Q) Lowest at 158,841.12

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -12.19% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shanghai Kaibao Pharmaceutical Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shanghai Kaibao Pharmaceutical Co., Ltd.

-10.31%

-0.02

27.32%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.14%

EBIT Growth (5y)

14.54%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.21

Sales to Capital Employed (avg)

0.37

Tax Ratio

15.03%

Dividend Payout Ratio

27.85%

Pledged Shares

Institutional Holding

ROCE (avg)

8.20%

ROE (avg)

6.40%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.48

EV to EBIT

13.48

EV to EBITDA

12.13

EV to Capital Employed

1.87

EV to Sales

3.56

PEG Ratio

17.99

Dividend Yield

1.66%

ROCE (Latest)

13.90%

ROE (Latest)

8.22%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

DIVIDEND PAYOUT RATIO(Y)

Highest at 48.23%

RAW MATERIAL COST(Y)

Fallen by -2.85% (YoY

CASH AND EQV(HY)

Highest at CNY 3,572.33 MM

DEBT-EQUITY RATIO (HY)

Lowest at -35.98 %

DIVIDEND PER SHARE(HY)

Highest at CNY 2.96

-21What is not working for the Company

INTEREST(9M)

At CNY 0.08 MM has Grown at inf%

NET SALES(Q)

At CNY 214.37 MM has Fallen at -26.61%

INTEREST COVERAGE RATIO(Q)

Lowest at 158,841.12

NET PROFIT(HY)

At CNY 100.4 MM has Grown at -22.66%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.24 times

Here's what is working for Shanghai Kaibao Pharmaceutical Co., Ltd.

Cash and Eqv

Highest at CNY 3,572.33 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -35.98 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Dividend per share

Highest at CNY 2.96

in the last five years

MOJO Watch

Company is distributing higher dividend from profits generated

DPS (CNY)

Dividend Payout Ratio

Highest at 48.23%

in the last five years

MOJO Watch

Company is distributing higher proportion of profits generated as dividend

DPR (%)

Raw Material Cost

Fallen by -2.85% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Kaibao Pharmaceutical Co., Ltd.

Interest

At CNY 0.08 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

At CNY 214.37 MM has Fallen at -26.61%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Interest Coverage Ratio

Lowest at 158,841.12 and Fallen

In each period in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Net Profit

At CNY 100.4 MM has Grown at -22.66%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

Inventory Turnover Ratio

Lowest at 1.24 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio